Equities analysts predict that RXi Pharmaceuticals Corporation (NASDAQ:RXII) will announce earnings per share (EPS) of ($0.11) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for RXi Pharmaceuticals Corporation’s earnings. RXi Pharmaceuticals Corporation reported earnings per share of ($0.34) in the same quarter last year, which would indicate a positive year over year growth rate of 67.6%. The business is expected to report its next earnings report on Thursday, November 9th.

According to Zacks, analysts expect that RXi Pharmaceuticals Corporation will report full-year earnings of ($0.74) per share for the current year. For the next fiscal year, analysts anticipate that the company will report earnings of ($0.57) per share. Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that that provide coverage for RXi Pharmaceuticals Corporation.

RXi Pharmaceuticals Corporation (NASDAQ:RXII) last released its quarterly earnings results on Thursday, August 10th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.11). During the same quarter last year, the firm earned ($0.34) EPS.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another site, it was illegally copied and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/08/17/brokerages-expect-rxi-pharmaceuticals-corporation-rxii-to-announce-0-11-earnings-per-share.html.

A hedge fund recently raised its stake in RXi Pharmaceuticals Corporation stock. Renaissance Technologies LLC increased its position in RXi Pharmaceuticals Corporation (NASDAQ:RXII) by 26.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 229,980 shares of the biotechnology company’s stock after buying an additional 48,200 shares during the period. Renaissance Technologies LLC owned approximately 3.49% of RXi Pharmaceuticals Corporation worth $164,000 as of its most recent SEC filing. 1.35% of the stock is owned by institutional investors.

Shares of RXi Pharmaceuticals Corporation (NASDAQ RXII) opened at 0.563 on Thursday. The firm’s market capitalization is $13.09 million. The firm’s 50 day moving average is $0.62 and its 200 day moving average is $0.66. RXi Pharmaceuticals Corporation has a 1-year low of $0.51 and a 1-year high of $2.93.

RXi Pharmaceuticals Corporation Company Profile

RXi Pharmaceuticals Corporation is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. The Company’s development programs are based on its self-delivering RNAi (sd-rxRNA) platform and Samcyprone, a topical immunomodulator.

Get a free copy of the Zacks research report on RXi Pharmaceuticals Corporation (RXII)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for RXi Pharmaceuticals Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RXi Pharmaceuticals Corporation and related companies with MarketBeat.com's FREE daily email newsletter.